Affordable Access

Publisher Website

20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw

Authors
Journal
The Lancet
0140-6736
Publisher
Elsevier
Publication Date
Volume
357
Issue
9260
Identifiers
DOI: 10.1016/s0140-6736(00)04219-7
Keywords
  • Primary Research
  • Research Letters
Disciplines
  • Medicine

Abstract

Summary We investigated subtype-dependent development of lamivudine resistance in hepatitis B virus (HBV) longitudinally in 26 consecutive patients (13 adw and 13 ayw carriers) during antiviral treatment of chronic hepatitis B. Lamivudine resistance developed in seven adw carriers and one ayw carrier. Risk of lamivudine resistance was significantly higher for adw carriers than for ayw carriers (p=0·03). We believe that the adw subtype of HBV is associated with a high risk of lamivudine resistance, which might be linked to simultaneous changes of the HBsAg that occurs with the emergence of resistance.

There are no comments yet on this publication. Be the first to share your thoughts.